Robert S Alter Selected Research

mavorixafor

1/2021

A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert S Alter Research Topics

Disease

4	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 07/2017
3	Disease Progression 01/2022 - 07/2017
3	Neoplasms (Cancer) 01/2021 - 07/2017
1	Chronic Renal Insufficiency 01/2021
1	Exanthema (Rash) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Autoimmune Hepatitis 01/2021
1	Edema (Dropsy) 07/2017
1	Epistaxis (Nosebleed) 07/2017
1	Fatigue 07/2017
1	Telangiectasis (Telangiectasia) 07/2017
1	Pericardial Effusion 07/2017
1	Diarrhea 07/2017
1	Progressive Multifocal Leukoencephalopathy 02/2002
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2002
1	Pneumonia (Pneumonitis) 02/2002
1	Virus Diseases (Viral Diseases) 02/2002
1	Cytomegalovirus Retinitis 02/2002

Drug/Important Bio-Agent (IBA)

2	NivolumabIBA 01/2022 - 01/2021
2	human ALK1-Fc fusion proteinIBA 01/2019 - 07/2017
2	Axitinib (AG 013736)IBA 01/2019 - 07/2017
1	IpilimumabIBA 01/2022
1	mavorixaforIBA 01/2021
1	Alanine (L-Alanine)FDA Link 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	Lipase (Acid Lipase)FDA Link 01/2021
1	Chemokine ReceptorsIBA 01/2021
1	PlatinumIBA 01/2020
1	pembrolizumabIBA 01/2020
1	Activin Receptors (Activin Receptor)IBA 01/2019
1	Tyrosine Kinase InhibitorsIBA 07/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2017
1	Rituximab (Mabthera)FDA Link 02/2002

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2020 - 02/2002
1	Autologous Transplantation 02/2002
1	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 02/2002
1	Immunotherapy 02/2002